Dana-Farber Cancer Institute

Articles

Dana-Farber Cancer Institute Earns Fifth Consecutive Magnet® Designation Recognizing Excellence in Nursing Practice and Patient Care

April 15th 2024

The American Nurses Credentialing Center has awarded Magnet® status to Dana-Farber Cancer Institute for the 5th time in a row.

Neuro-Inclusive Oncology Care and Empowerment Program

April 8th 2024

Dana-Farber details how their Neuro-Inclusive Oncology Care and Empowerment program was developed to help physicians and other providers treat cancer in patients who have intellectual and/or developmental disabilities.

Scott Armstrong Named Senior Vice President for Drug Discovery and Chief Research Strategy Officer at Dana-Farber

April 2nd 2024

Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute.

Remote Online Genetic Education Programs Can Spur Testing for Inherited Susceptibility to Cancer, Study Suggests

March 21st 2024

In the GENERATE study, 90% of those who viewed an online genetic education program chose to be tested for inherited predisposition to pancreatic cancer.

Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice

March 18th 2024

The Third Transatlantic Exchange in Oncology Conference will focus on liquid biopsy as an emerging approach in precision cancer medicine.

Kidney Cancer Treatments and Tumor Biology Can Activate Different Immune-Modifying Processes in Patients

March 5th 2024

Different immunomodulatory mechanisms are at work depending on the type of treatment and the genetic makeup of the cancer in RCC.

Cathy Wu, MD, Wins Prestigious Sjöberg Prize for Cancer Vaccine Research

February 19th 2024

Catherine J. Wu, MD, of Dana-Farber Cancer Institute, has been awarded the Sjöberg Prize today for her pioneering research in the field of personalized vaccines to treat cancer.

Elevated Blood Levels of NT-proBNP in Cancer Survivors Link With Higher Risks of Death

February 2nd 2024

Cancer survivors with elevated levels of NT-proBNP have a higher risk of death, according to an analysis conducted by Dana-Farber Cancer Institute.

Dana-Farber Researchers Receive Prestigious 2023 Outstanding Investigator Award from National Cancer Institute

January 26th 2024

Dana-Farber Cancer Institute researchers are the recipients of the Outstanding Investigator Award from the NCI, part of the National Institutes of Health.

More Than 125 Dana-Farber Affiliated Faculty Named as 2024 Top Doctors™ in Boston Magazine

January 24th 2024

More than 125 Dana-Farber affiliated doctors have been included in Boston magazine's annual "Top Doctors" guide.

Study Suggests Progress and Opportunity for Fertility Care for Young Breast Cancer Patients

January 22nd 2024

To understand how fertility concerns affect breast cancer treatment decisions, researchers analyzed data from the Young and Strong study.

Blood Test Distinguishes Neuroendocrine Subtype of Advanced Prostate Cancer

January 16th 2024

Blood test uses cell-free DNA methylation to quantify tumor burden and distinguish neuroendocrine prostate cancer from prostate adenocarcinoma.

FDA Approves Kidney Cancer Therapy After Dana-Farber-Led Research Shows Improved Outcomes for Patients with Advanced Disease

December 31st 2023

Belzutifan, a HIF-2α inhibitor, has been approved by the FDA for the treatment of patients with advanced kidney cancer previously treated with immune checkpoint inhibitors and antiangiogenic therapies.

Study Finds Associations Between T Cell Diversity in Peripheral Blood and Patient Age, Stage of Breast Cancer Development

December 28th 2023

Researchers at Dana-Farber Cancer Institute found that the diversity of T cells in peripheral blood declines with age in patients with breast cancer and, in younger patients, is lower in those diagnosed with metastatic disease than with ductal carcinoma in situ.

Study Finds Associations Between T Cell Diversity in Peripheral Blood and Patient Age and Stage of Breast Cancer Development

December 24th 2023

Researchers at Dana-Farber Cancer Institute have found that the diversity of T cells in peripheral blood declines with age in patients with breast cancer and, in younger patients, is lower in those diagnosed with metastatic disease than with ductal carcinoma in situ.

Dana-Farber Launches New Centers to Detect and Intercept Cancer

December 10th 2023

Dana-Farber Cancer Institute is launching a first-of-its-kind, integrated clinic to increase early detection of precancerous conditions and to prevent cancer from arising in individuals at increased risk for the disease.

Dana-Farber Researchers to Present Findings at 2023 San Antonio Breast Cancer Symposium

December 6th 2023

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 46th annual San Antonio Breast Cancer Symposium, December 5–9, 2023.

Dana-Farber Research Fellow Tyler Miller, MD, PhD, Receives £600,000 Grant From the Brain Tumour Charity

November 27th 2023

The Brain Tumour Charity awarded a Junior Fellows grants of £600,000 over four years - the first of its kind - to Dana-Farber Research Fellow Tyler Miller, MD, PhD.

Dual-Action Drug Produces Positive Results in Patients With Advanced Neuroendocrine Tumors, Trial Finds

November 16th 2023

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

Oncology Researchers Raise Ethics Concerns Posed By Patient-Facing Artificial Intelligence

November 13th 2023

In a new paper in JCO Oncology Practice, bioethics researchers at Dana-Farber Cancer Institute call on medical societies, government leaders, clinicians, and researchers to work together to ensure AI-driven healthcare preserves patient autonomy and respects human dignity.